NCT00171587CompletedPhase 1
A Phase IB, Open-label, Dose-escalating Study of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Novartis
- Enrollment
- 22
- Locations
- 2
- Primary Endpoint
- Safety
Study Overview
Brief Summary
The objective of this study is to assess the safety, tolerability, dose limiting toxicity, and maximum tolerated dose of vatalanib administered orally once daily in combination with capecitabine in patients with advanced cancer. The study is also designed to determine the effect of vatalanib on the pharmacokinetics of capecitabine and the effect of capecitabine on the pharmacokinetics of vatalanib, and to describe the anti-tumor activity of this combination regimen.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients with histologically confirmed advanced cancer that is refractory to standard therapy or for which no standard therapy exists (for dose escalation phase of the study only)
- •Patients with histologically confirmed metastatic solid tumors or colorectal cancer presenting with metastatic disease and who received up to four prior chemotherapies for metastatic disease (for dose expansion phase of the study only)
- •Measurable or non-measurable disease as determined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
- •Age >= 18 years old
- •Karnofsky Performance Status (KPS) of >= 70
- •Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
- •Hemoglobin (Hgb) >= 9 g/dl
- •Platelets >= 100 x 10^9/L
- •Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) <= 3.0 x upper limit of normal (ULN)
- •Serum bilirubin <= 1.5 x ULN
- •Serum creatinine <= 1.5 x ULN and 24-hour creatinine clearance >= 50 ml/min
- •Total urinary protein in a 24-hour urine collection <= 500 mg
- •Life expectancy of greater than 3 months
- •Written informed consent obtained according to local guidelines
Exclusion Criteria
- •Patients who have acute or chronic leukemias, lymphoma, or multiple myeloma
- •Patients who have known bone marrow involvement with tumor
- •Patients with a history of primary central nervous system tumors or brain metastases
- •Prior allogeneic, syngeneic, or autologous bone marrow transplant or stem cell transplant
- •Patients who have had more than two prior chemotherapy regimens for metastatic disease (for dose escalation phase of the study only)
- •Patients who have received chemotherapy less than 4 weeks (6 weeks for nitrosoureas or mitomycin-C and 2 weeks for vincristine) prior to entry on this study or who have not recovered from side effects of such therapy
- •Patients who have received immunotherapy within 2 weeks or who have not recovered from side effects of such therapy
- •Patients who have received radiotherapy within 2 weeks or who have not recovered from side effects of such therapy. The site of radiotherapy should not be the only site of measurable disease.
- •Major surgery within 2 weeks prior to entry on this study or patients who have not recovered from side effects of such therapy
- •Patients who have received investigational drugs within 4 weeks prior to entry on this study or who have not recovered from side effects of such therapy
- •Patients who are pregnant or breast feeding, or adults of reproductive potential not employing an effective method of birth control. Oral, implantable, or injectable contraceptives are not considered an effective method of birth control for this study. (Women of childbearing potential must have a negative serum pregnancy test 48 hours prior to administration of chemotherapy).
- •Concurrent severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, congestive cardiac failure, myocardial infarction within 6 months, poorly controlled hypertension, history of labile hypertension, history of poor compliance with antihypertensive regimen, chronic renal disease, or active uncontrolled infection) which could compromise participation in the study
- •Acute or chronic liver disease (e.g., hepatitis, cirrhosis)
- •Confirmed diagnosis of HIV infection
- •Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of PTK787/ZK 222584 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, bowel obstruction, or inability to swallow the capsules/tablets)
- •Patients who are taking Coumadin (warfarin sodium)
- •Patients unwilling to or unable to comply with the protocol
- •Other protocol-defined inclusion/exclusion criteria may apply.
Outcomes
Primary Outcomes
Safety
Tolerability
Secondary Outcomes
- Pharmacokinetics
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 1
Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South AfricaSARS-CoVSARS-CoV-2NCT05938075Vaccine Company, Inc.130
Completed
Phase 1
Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United StatesSARS-CoVSARS-CoV-2NCT05870839Vaccine Company, Inc.121
Completed
Phase 1
Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple SclerosisPrimary Progressive Multiple SclerosisSecondary Progressive Multiple SclerosisNCT01191996Innate Immunotherapeutics34
Not yet recruiting
Phase 1
Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of UB-221 in Healthy VolunteersChronic Spontaneous UrticariaNCT04404023UBP Greater China (Shanghai) Co., Ltd15
Recruiting
Phase 1
A Study With NKT3964 for Adults With Advanced/Metastatic Solid TumorsSolid TumorAdvanced Solid TumorSolid Tumor, AdultMetastatic TumorOvarian NeoplasmsOvarian CarcinomaMetastatic Ovarian CarcinomaEndometrial NeoplasmsEndometrial DiseasesMetastatic Endometrial CancerTriple Negative Breast CancerMetastatic Endometrial CarcinomaAdvanced Endometrial CarcinomaAdvanced Ovarian CarcinomaAdvanced Gastric CarcinomaMetastatic Gastric CancerMetastatic Gastric CarcinomaSmall Cell Lung CarcinomaTriple Negative Breast NeoplasmsPlatinum-resistant Ovarian CancerPlatinum-refractory Ovarian CarcinomaCCNE1 AmplificationHormone Receptor Negative Breast CarcinomaHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastProgesterone-receptor-positive Breast CancerOvarian CancerGastric CancerSmall Cell Lung CancerNCT06586957NiKang Therapeutics, Inc.150